Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR) on November 21, 2021. The rights are to develop, manufacture and commercialize the investigational antibody obexelimab. Under the terms of the new agreement, Zenas will issue to Xencor a warrant giving Xencor the right to acquire additional Zenas equity, such that Xencor?s total equity in Zenas would be 15% of its fully diluted capitalization following the closing of Zenas? next round of equity financing, subject to certain requirements. Xencor is also eligible to receive up to?$480 million?based on the achievement of certain clinical development, regulatory and commercialization milestones and is eligible to receive tiered, mid-single digit to mid-teen percent royalties upon commercialization of obexelimab, dependent on geography. Zenas BioPharma Limited completed the acquisition of Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).